PA5-28710

antibody from Invitrogen Antibodies

Targeting: EZH1 KIAA0388, KMT6B

Western blot

Immunohistochemistry

Antibody data

Submit

Validation data

Product number: PA5-28710 - Provider product page
Provider: Invitrogen Antibodies
Product name: EZH1 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Synthetic peptide
Description: Recommended positive controls: 293T, A431, H1299, HeLaS3, HepG2, Molt-4, Raji. Predicted reactivity: Rhesus Monkey (100%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

EZH1 protein structure - PA5-28710 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 1 EZH1 and EZH2 are differently expressed in naive B cells and MCL. (A) Expression of EZH1 and EZH2 in reactive germinal centers and MCL cases were determined by immunohistochemistry (20 x). (B) Overall survival of MCL cases was analyzed by Kaplan-Meier plot based on the expression of EZH1 and EZH2. (C) The mRNA and (D) protein levels of EZH1 and EZH2 as well as H3K27me3 in naive B cells and 4 MCL cell lines were determined by qRT-PCR and Western blot. (E) Gene sequence alignment showing the representative Y641 status of EZH2 in four MCL cell lines. ** P < 0.01.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 3 Double inhibition of EZH1/2 represses the proliferation of MCL cells. (A, B) Z138-EZH2 KD cells were introduced with CRISPR/cas9 system targeting EZH1 . After 4 weeks of puromycin and Blasticidin double selection, the EZH1/EZH2 expression was determined on mRNA and protein levels respectively. (C-E) Upon EZH1/EZH2 double-KD, cell proliferation was determined by MTS assay, cell cycle progression and apoptosis were determined by flow cytometry. (F) Z138 and Mino cells were treated with 8mum of UNC1999 for 48 h, and measured with EZH1/EZH2 mRNA expression by qRT-PCR. (G) Z138 and Mino cells were treated with increasing dose of UNC1999 for 48 h and determined with the EZH2, EZH1 and H3K27me3 level. (H-J) Z138 and Mino cells were treated with increasing dose of UNC1999 and determined with cell proliferation, cell cycle progression and apoptosis. Data are represented as the mean +- SD. All experiments were repeated at least three times. * P < 0.05 and ** P < 0.01.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: S1 Full gel images of Western blot depicted in Figure 1D and Figure 3G . (A) Protein levels of EZH1 and EZH2 as well as H3K27me3 in naive B cells and 4 MCL cell lines were determined by western blot. (B) Z138 and Mino cells were treated with increasing dose of UNC1999 for 48 h and determined with the level of EZH2, EZH1 and H3K27me3.